<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18">Anti-TNFα therapy, such as adalimumab or infliximab, is used in the management of several autoimmune inflammatory diseases such as RA, inflammatory bowel disease, and ankylosing spondylitis [
 <xref ref-type="bibr" rid="CR48">48</xref>]. Experimental studies suggest a potential rationale for use of anti-TNF therapy in viral pneumonia [
 <xref ref-type="bibr" rid="CR46">46</xref>]. It has been proposed that a single infusion of anti-TNFα antibody can significantly reduce the amount of TNF in the blood [
 <xref ref-type="bibr" rid="CR49">49</xref>], suggesting a possible anti-inflammatory benefit in COVID-19. Besides its classical effect on TNFα inhibition, anti-TNFα may also induce the downregulation of ACE2 expression and shedding [
 <xref ref-type="bibr" rid="CR47">47</xref>, 
 <xref ref-type="bibr" rid="CR50">50</xref>]. However, there is also concern that anti-TNFα therapy might increase the risk of bacterial or fungal superinfections [
 <xref ref-type="bibr" rid="CR49">49</xref>].
</p>
